Shares of Amphastar Pharmaceuticals (AMPH) are soaring 9.26% in Monday's trading session following a significant regulatory milestone. The company announced that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP, a generic drug used to treat iron deficiency anemia in patients with chronic kidney disease.

The FDA approval covers single-dose vials in dosages of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, highlighting the company's commitment to developing complex generics and maintaining high regulatory standards. The company plans to launch the product in the third quarter of 2025, potentially opening up a substantial new revenue stream.

Investors are reacting positively to this development, as it positions Amphastar to enter a lucrative market. The comparable product, Venofer®, has reported sales of approximately $513 million over the past year. This approval not only validates Amphastar's R&D capabilities but also strengthens its product portfolio in the specialty pharmaceutical sector. The significant stock price increase reflects market optimism about the potential revenue boost this new product could bring to Amphastar and the company's ability to successfully navigate the FDA approval process for complex generics.